Biopharm, the most effective way to treat a disease is to prevent its development in the first place. Even though I believe that bavituxmab might have F.O.Y. capabilities, does not interfere with the challenges that must be considered in actually achieving immunity.
I would challenge anyone to theorize how Bavituxmab could incounter an incipient tumor mass and trigger an effect of immunity, knowing in the least these two obstacles.
1) CTL (cytotoxic T lymphocytes) responses almost always begin in lymph nodes
2) The relative lack of high avidity T cell receptors are a major reason why immune responses towards tumor antigens are often non-protective.
This is just the tip of the iceberg when considering bavituxmab as a vaccine. Remember, in order for there to be immunity the most basic thing must happen, and that is, "memory anti-tumor CTL response". I contemplate this everyday, because I know there's an answer in bavituxmab somewhere.
All the best,
John
News 
Market Data 
Discover 
